Nick Spittal Comments on Velocity’s Membership With Advarra’s Gene Therapy Ready Site Network

As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.” All Velocity sites are fully prepared … Read more

VISION Reaches $2.5 Million in Patient Stipends Paid Globally

Another major milestone for Velocity — more than $2.5 million in patient study stipends have been paid globally through our VISION Engage app! With VISION Engage, patients can seamlessly manage their trial journey while receiving study stipends directly through the app, making participation more convenient. Together with VISION Engage app users, we’re transforming clinical trial … Read more

Dr. Watz Publishes 250th Paper, Leads Velocity’s Ahrensburg, Germany Site as the Top Enroller for a Global COPD Trial

Congratulations to Henrik Watz, MD, PhD, and our site in Ahrensburg (formerly Velocity Grosshansdorf), Germany, which is currently the top enroller for a global COPD trial! Dr. Watz has just published his 250th full paper, detailing results from the Phase 2 AIRLEAF trial. This study could pave the way for new treatment options in bronchiectasis, … Read more

Velocity Has Supported Research for 12 Products That Have Received FDA Approval in 2024

Velocity sites and investigators have now supported research for 12 products that received U.S. FDA approval in 2024! This year’s groundbreaking approvals include: Ebglyss (lebrikizumab-lbkz) by Eli Lilly, a new treatment for moderate to severe atopic dermatitis (eczema). mRESVIA by Moderna, a vaccine to protect seniors from lower respiratory tract infections caused by RSV. Livdelzi … Read more

Raghu Punnamraju, CTO, for VentureBeat: Why data science alone won’t make your product successful

In this new article for VentureBeat, Raghu Punnamraju, Chief Technology Officer at Velocity, discusses why data science alone is not enough to ensure product success. In this insightful piece, Raghu explores the importance of blending technical excellence with commercial understanding, highlighting the need for lean-value principles, the role of AI, and the power of data … Read more

Paul Evans Featured in Business North Carolina Article on AI in the State’s Clinical Research Industry

Paul Evans was recently featured in a Business North Carolina article discussing the emerging impact of artificial intelligence on North Carolina’s clinical research industry. As Paul notes, “Our industry is in the same place as most people with AI. We’ve seen a step change. Everybody started with efficiency gains, back-office functions. Then you move on … Read more

Drs. Essink and Overcash Author Article Featured in Nature Communications for Moderna COVE Study

Brandon Essink, MD, CPI, and J. Scott Overcash, MD, were authors of a recent Nature Communications article, “Long-term safety and effectiveness of mRNA-1273 vaccine in adults: COVE trial open-label and booster phases.” From the article: “Boosting elicited greater immune responses against SARSCoV-2 than primary vaccination, irrespective of prior SARS-CoV-2 infection. Primary vaccination and boosting with … Read more

VISION Reaches $2 Million in Patient Stipends Paid Globally

Since launching in-app stipend payments, Velocity has paid more than $2 million to patients globally through VISION. The mobile app has also contributed to more than 2,500 patient randomizations, empowering users to get matched with clinical trials, self-screen, and self-schedule visits, all at times that are most convenient for them. Together, VISION Engage and VISION … Read more

Kris Kowdley, MD, Supported Research Leading to Accelerated FDA Approval of Gilead’s Livdelzi® for Primary Biliary Cholangitis

Another milestone for patients with primary biliary cholangitis (PBC) — Gilead’s Livdelzi® (seladelpar) has received accelerated FDA approval as a second-line treatment for PBC. Kris Kowdley, MD, AGAF, FAASLD, FACP, FAC, was an author of the Phase 3 trial results published in the New England Journal of Medicine. Congratulations to Gilead, Dr. Kowdley, the team … Read more